Synthetic DNA
Synthetic DNA has become a critical component of a wide range of emerging and established industries with global demand increasing rapidly. Current approaches are unable to keep up with the quantity, quality and complexity required for cutting-edge technologies.
The current production model cannot deliver the future demand for DNA.
Services
Whether it is custom synthesis, contract research into new compounds or material supply, you can rely on our experienced multidisciplined team to deliver the best solutions tailored to your specific needs.
NunaBio Range of Services.
Features
NunaBio Service Features.
Short Oligonucleotides.
Customised DNA oligos according to your specifications. We offer a range of purification options and scales.
Closed-ended DNA.
Linear, double stranded and covalently closed DNA constructs of a range of lengths and scales.
A Range of Modifications.
Pre-made building blocks & in-house expertise: We have the labelled nucleotides you need.
Repetitive Sequences.
Homologous DNA fragments with a range of repeating unit lengths and multiple spacer sequences available.
Long Genes/Gene Fragments.
Genes and gene fragments suited for a variety of workflows and applications including protein evolution, gene construction, antibody engineering, and more.
Homopolymers.
Consecutive identical bases as part of a given sequence or individual constructs.
Get in touch
Technology
Our multi-patented technology produces synthetic DNA using enzymes rather than hazardous chemicals.
NunaBio Product Benefits.
-
High purity
-
Scaleable
-
Fast turnaround
-
Cell-free
-
Complex sequences
-
Low cost
Market
NunaBio serves a Total Addressable Market as a service provider and platform manufacturer.
Reagents.
7
by 2026
Penetrated Market
Global microarray market
to reach $7.4bn by 2026
Biosensors.
36
by 2026
Target Market
Global market to reach
$36.7bn by 2026
Synthetic Biology.
30
by 2026
Qualified Available
Global gene synthesis biology
market to reach $30.7bn by 2026
Gene Therapies.
21
by 2026
Available Market
Global gene therapy market
expected to reach $21.2bn by 2026
Vaccines.
142
by 2026
Available Market
Global vaccine market
expected to reach $142.2bn by 2026
Technology
Our core technology is extremely versatile and can also be applied to a wide range of adjacent markets.
NunaBio Ltd
Bedson Building
Newcastle University
Newcastle upon Tyne
NE1 7RU
T.+44 (0) 330 2292700
info@nunabio.com
